Literature DB >> 4062389

IgA serum levels and disease activity in ankylosing spondylitis: a prospective study.

M J Franssen, L B van de Putte, F W Gribnau.   

Abstract

We investigated the possible association between serum IgA, IgM, and IgG and disease activity in a longitudinal study of 48 weeks' duration in 38 male patients with active ankylosing spondylitis receiving regular treatment with either phenylbutazone or diflunisal. Throughout the study serum IgA levels correlated most frequently with chest expansion and lumbar flexion index, and patients with extensive radiological changes also had the highest serum IgA levels. Likewise, changes in IgA, but not in IgM and IgG, correlated with changes in a composite index of disease activity (IDA). Changes in erythrocyte sedimentation rate (ESR) showed a similar correlation with changes in IDA, whereas changes in serum IgA and ESR showed no consistent correlation, suggesting that both parameters reflect different aspects of disease. Serum IgA, ESR, and IDA values all decreased during regular drug treatment, suggesting a disease modifying effect of the non-steroidal anti-inflammatory drugs (NSAIDs) studied. Regular measurement of serum IgA may be useful in the assessment of disease activity of ankylosing spondylitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4062389      PMCID: PMC1001771          DOI: 10.1136/ard.44.11.766

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Effect of ankylosing spondylitis on ventilatory function.

Authors:  M C ROGAN; C D NEEDHAM; I McDONALD
Journal:  Clin Sci       Date:  1955-02       Impact factor: 6.124

Review 2.  Secretory immunoglobulins.

Authors:  T B Thomasi
Journal:  N Engl J Med       Date:  1972-09-07       Impact factor: 91.245

3.  Arthritis associated with Yersinia enterocolitica infection.

Authors:  P Ahvonen; K Sievers; K Aho
Journal:  Acta Rheumatol Scand       Date:  1969

4.  Assessment of the flexibility of the lumbar spine. A pilot study in children and adolescents.

Authors:  J A van Adrichem; J K van der Korst
Journal:  Scand J Rheumatol       Date:  1973       Impact factor: 3.641

5.  Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone.

Authors:  J W Boersma
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

6.  An objective clinical study of chest expansion.

Authors:  J M Moll; V Wright
Journal:  Ann Rheum Dis       Date:  1972-01       Impact factor: 19.103

7.  Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease.

Authors:  R W Ebringer; D R Cawdell; P Cowling; A Ebringer
Journal:  Ann Rheum Dis       Date:  1978-04       Impact factor: 19.103

8.  Faecal carriage of klebsiella by patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  R E Warren; D A Brewerton
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

9.  Haematology and biochemistry of ankylosing spondylitis.

Authors:  M J Kendall; D S Lawrence; G R Shuttleworth; A G Whitfield
Journal:  Br Med J       Date:  1973-04-28

10.  Frequency of faecal Klebsiella aerogenes in patients with ankylosing spondylitis and controls with respect to individual features of the disease.

Authors:  C J Eastmond; H E Willshaw; S E Burgess; R Shinebaum; E M Cooke; V Wright
Journal:  Ann Rheum Dis       Date:  1980-04       Impact factor: 19.103

View more
  22 in total

Review 1.  Small intestinal mucosal protection mechanisms and their importance in rheumatology.

Authors:  S O'Mahony; A Ferguson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

2.  Increased levels of serum IgA as IgA1 monomers in ankylosing spondylitis.

Authors:  H Hocini; S Iscaki; C Benlahrache; L Vitalis; X Chevalier; B Larget-Piet; J P Bouvet
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 3.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

4.  Serum secretory immunoglobulins in ankylosing spondylitis.

Authors:  D Wendling; J M Didier; E Seilles
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

5.  Immunoglobulin A in the skin of patients with ankylosing spondylitis.

Authors:  A Collado; R Sanmarti; I Bielsa; T Castel; E Kanterewicz; J D Cañete; M A Brancós; J Rotes-Querol
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

6.  IgA serum levels and disease activity in ankylosing spondylitis.

Authors:  J J Calabro
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

7.  Immunoglobulin A and C reactive protein levels in ankylosing spondylitis.

Authors:  A Collado; R Sanmarti; M A Brancós; E Kanterewicz; T Gallart; J Rotés-Querol; A Cobos
Journal:  Ann Rheum Dis       Date:  1987-09       Impact factor: 19.103

8.  Immune complexes in ankylosing spondylitis.

Authors:  I L MacLean; J R Archer; M I Cawley; B L Kidd; B P O'Hara; F S Pegley; P W Thompson
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis.

Authors:  K M Sanders; A Hertzman; M R Escobar; B H Littman
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

10.  IgA antibodies in HLA-B27 associated acute anterior uveitis and ankylosing spondylitis.

Authors:  S H Sprenkels; J Uksila; R Vainionpää; P Toivanen; T E Feltkamp
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.